Insulet, a maker of insulin delivery systems, is currently facing a temporary setback due to a retention issue with new Type 2 diabetes patients. While the company reported a 23.5% year-over-year revenue growth in the last quarter, its stock fell approximately 20% after it lowered its full-year revenue forecast, primarily due to a stumble in onboarding new patients.
Analysts have reacted with downgrades, but the consensus view is that these reactions are overblown. Insulet's Omnipod insulin pump is well-positioned to benefit from the growing adoption of GLP-1 weight loss drugs, which are expected to increase the number of patients requiring insulin therapy. The company's international growth is also strong, with revenue rising between 30% and 32%.
Insulet's competitive advantages include its tubeless design and a recurring revenue model that allows for easier patient access. Despite the recent stock decline, analysts suggest that a modest re-rating could lead to a price target of $196, representing over 30% upside from current levels.
Insulet's balance sheet remains strong, and the company is taking steps to improve patient retention, which could further enhance its growth trajectory in the Type 2 diabetes market